Home / Drug development / ADME-Tox / In vitro
In vitro ADME-Tox
Our in vitro ADME CRO services support small molecules, peptides, oligonucleotides, ADCs, PROTACs and other complex modalities.
Whether run independently or as part of an integrated program, they deliver decision-ready data to identify risks early, strengthen design choices and prepare candidates for IND. Each assay is customized with you to fit the science and stage of your project
Studies include:
- Metabolic stability in various matrices, e.g., microsomes, hepatocytes, recombinant enzymes, low clearance systems
- Biotransformations, metabolite profiling and identification in vitro and in vivo
- Drug-drug interaction studies (enzyme phenotyping, CYP inhibition, induction and transporter assays)
- Plasma protein and tissue binding assessments
- Quantitative bioanalysis with state-of-the-art methods and instrumentation tailored to your needs (LC-MS/MS, LC-HR/MS, qPCR, ELISA, etc.)
- Permeability studies
- Solubility and physicochemical property measurements
- In vitro toxicology assays, such as drug-induced liver injury assessment (DILIscope)
- Physicochemical characterization
- In vivo DMPK capabilities
Related services
ADME services delivered by Admescope
All ADME services, including in vitro ADME, in vivo PK screening, ADME-Tox and in vivo DMPK are performed by Admescope (a Symeres company).
In vitro ADME with regulatory depth
Applied expertise
Decades of ADME-Tox and DMPK experience that turns complex data into clear, decision-ready results.
Tailored delivery
Rapid screens or full regulatory studies designed around your compound, timeline, and scientific question.
Connected teams
US and European scientists work as one group for consistent data, communication and oversight
Integrated ADME-Tox capabilities
Our in vitro ADME-Tox studies connect directly with in vivo DMPK to give a full picture of exposure, safety and metabolism.
Integrated data across studies reduces rework and uncertainty, which keeps decisions clear and programs moving confidently from discovery to IND.
What do our partners say?
“If the compound can be made, Symeres will undoubtedly find out a good way to make it.”
Dooyoung Jung, CEO
Pinotbio
“The progression was really phenomenal. I am truly impressed. There is a world of difference between you and other CROs.”
Start-up Founder
Biotech
“We are developing the most complex molecule that is built at this time in the world…We work with a lot of CROs, also chemistry CROs, and so far Symeres has done the best job with respect to transparency and also to troubleshoot the problems and find a solution. Over the years we have been really impressed with the work that Symeres has done.”
Founder
Biotech
“A sign that things are going well - we keep coming to you. We’ve given Symeres five or six different projects already. That’s almost unheard of for us.“
Senior Director, Manufacturing
Top 10 global pharma
“The team is making short work of these targets, so we will have to start thinking of some additional targets!”
Director
Biotech
“Through our dedicated FTE resource at Symeres we have achieved remarkable results, not only by developing a new “aspirational” synthetic route but also by significantly improving the current one to deliver a sustainable route for commercial production and giving us two options for late development.”
Associate Director
Large pharma, Europe
“They’ve always met or exceeded my expectations - that’s why I continue to come back, company after company, year after year.”
Allen Horhota, Vice-President Platform & Delivery
Seamless Therapeutics
“I would like to extend my thanks for the excellent work Symeres has done in synthesizing the API for Part 1 of our project. Your communication throughout the process was outstanding, and the sense of urgency with which you operated allowed us to complete this phase promptly and efficiently.”
Leader
Large biotech
“We’ve been with them…over 10 years. The cost, the flexibility - the value is just so strong. That’s why we’ve stuck with them.”
Senior Director, CMC
Biotech
Your discovery and development partner
Symeres support small-molecule programs from discovery through IND with openness, agility and scientific depth.
Our connected teams in Europe and North America share data transparently, adapt quickly to new results, and stay accountable from first experiments to IND, to keep your progress clear, connected and continuous.
Resources we think you'll love
CDMO red flags you can’t ignore: Regulatory shortfalls and misalignment
Whitepaper
5 CDMO red flags you can’t ignore: A guide for biotechs and pharma
Whitepaper
CDMO red flags you can’t ignore: Underestimating technology transfer complexity
Blog
O.N.E Symeres: A practical approach to real-world drug development
Whitepaper
CDMO red flags you can’t ignore: Undefined or shifting project scope
Whitepaper
Accelerating chemical innovation: Unveiling Symeres’ parallel chemistry
Webinar | On-demand
From racemic to pure the art and science of enantiomer separation
Whitepaper
IND & IMPD enabling developability roadmap
Whitepaper
Innovations in unnatural amino acids: Advancing functional diversity and applications
Whitepaper
Leveraging copper-catalyzed ullmann-type cross-coupling reactions in PR&D
Whitepaper
Managing nitrosamines in the pharmaceutical industry: A comprehensive approach
Whitepaper
Optimizing solid-state properties and enhancing API bioavailability through physicochemical prediction
Whitepaper
Stable isotope-labeled compounds
Whitepaper
Unlocking the potential of high-throughput screening: Symegold library design and expansion insights
Interviews
Insights into drug discovery and development 2025
Interviews
Interview with the computer-aided drug design (CADD) department
Interviews
Meet the Organix Director, Mario Gonzalez
Interviews
Interview with the new Managing Director of Symeres Groningen
Interviews
An interview with Yadan Chen and Paul O’Shea
Interviews
An interview with Anu Mahadevan and Paul Blundell
Blog
Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same
Webinar | On-demand
In vivo pharmacokinetic experiments in preclinical drug development
Webinar | On-demand
Accelerating medicinal chemistry by rapid analoging
Webinar | On-demand
Solid-state chemistry part II: Optimal form selection by controlled crystallization
Webinar | On-demand
Route scouting for kilogram-scale manufacturing of APIs
Webinar | On-demand
Solid-state chemistry part I: Introduction
Speak with our in vitro ADME-Tox experts
Discuss the discovery and development of your next breakthrough